Skip to main content

Table 1 Injection data for the PET study

From: Synthesis and evaluation in rats of homologous series of [18F]-labeled dopamine D2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers

Tracer Injected activity, MBq/rat Injected dose, nmol/kg Rats per treatment group (saline/raclopride) Pre-treatment time interval, min
[18F]FEt-AMC13 9.4 ± 1.2 0.55 ± 0.14 4/4 47 ± 27
[18F]FBu-AMC13 20.8 ± 10.6 0.45 ± 0.26, 10.4, 11.0a 3/3 52 ± 19
[18F]FEt-AMC15 26.6 ± 15.2 1.06 ± 0.65 3/3 48 ± 10
[11C]raclopride 16.9 ± 5.3 1.26 ± 0.16 4 (saline only) 36 ± 3
  1. One rat in the saline-treated group and one rat in the raclopride-treated group were injected, respectively, with 10.4 and 11.0 nmol/kg tracer. As all outcome measures (time-activity curves, uptake ratios) obtained from these animals were very close to the results from other animals in the corresponding groups, these results were not omitted or separated, but combined with the rest of the data